anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides application of deubiquitinase USP37 serving as a drug target in screening drugs for treating drug-resistant breast cancer. The invention also provides application of the deubiquitinase USP37 in preparing a reagent for diagnosing drug-resistant breast cancer. The invention also provides application of the deubiquitinase USP37 in preparing a medicine for treating breast cancer, wherein the treatment is to inhibit the proliferation of breast cancer cells by targeting USP37 and combining cisplatin medication. Compared with Cisplatin, the invention has more obvious effect of killing breast cancer. Is more specific than the BLM inhibitor ML216 and does not produce off-target effects. The invention aims to confirm that the key role of the deubiquitinase USP37 in the occurrence and development of the breast cancer is played, proves that the target USP37 can be combined with chemical medicaments or combined radiation therapy to more effectively treat the breast cancer, and provides a theoretical basis for effectively overcoming the drug resistance problem in the breast cancer treatment.
A smoking abatement and cigarette replacement device comprises a storage chamber, a seepage body, a straw and medicine liquid, wherein the storage chamber is hollow, one end of which is provided with screw and the other end thereof is provided with a rubber cover. The seepage body is composed of a seepage groove and a seepage tip. The straw is composed of a straw body and a gas flow opening. The medicine liquid is composed of fructus schizandrae, radix ophiopogonis, borneol, astragalus root, fructus momordicae, liquorice, pericarpium citri Reticulatae, field mint, honeysuckle, notoginseng etc. When in use, medicine liquid is added into the storage chamber, the rubber cover is bucked on, the seepage body is inserted into another end, and then is buckled with the screw through the straw. The straw is put into mouth to be used for inspiration like smoking. When straw, seepage body and storage chamber are combined, structure according to Venturi tube principle is provided, since the seepage body is provided with structure generating wool phenomenon, tip effect occurs when smoke passes through the seepage tip, efficient components of anion in the atomized gas enters into mouth, trachea and lung, thereby achieving objectives of  abating smoking and cleaning harmful substances in lung.
Storage vessels filled with waste radioactive material are taken underground using the entrance of an operating or abandoned mine. The vessels are deposited in chambers cut into previously undisturbed rock below the `karst' water level. The chambers are filled and each chamber, section and the whole `field' is sealed off against water. Transport is always carried out against the flow of ventilation air. The underground storage area is located below the `karst' water level, in rock formation with a max. of 10 power(-6) cm/sec. water leakage, at least 100 metres from the bounary of the formation, and at least 300 metres from rock, which is already disturbed. The storage area has a max. of two connections to the surface, these are for inward transport and tie-in. The storage area is divided into sections in which access roads and storage chambers are cut. Each chamber is surrounded by protective rock. Full chambers and sectors are sealed with water tight structures
Natural full human monoclonal antibody CBB 1 injection：Each dose (2.5ml) contained 0.5 mg / natural monoclonal antibody ml CBB 1 Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection Character: colorless to pale green and yellow liquid Specification: 1.25 mg (2.5 ml) / bottle Mode of administration: intramuscular injection of the vastus lateralis muscle. Usage and dosage: The injection dose was calculated according to the group and body weight of the volunteer. On day 0, unilateral or bilateral extrafemoral muscle group injections were selected by dose, with no more than 5 mL at each site, and at least 2.5 cm apart.
BACKGROUND: The rebound of influenza A (H1N1) infection in post-COVID-19 era recently attracted enormous attention due the rapidly increased number of pediatric hospitalizations and the changed characteristics compared to classical H1N1 infection in pre-COVID-19 era. This study aimed to evaluate the clinical characteristics and severity of children hospitalized with H1N1 infection during post-COVID-19 period, and to construct a novel prediction model for severe H1N1 infection.
METHODS: A total of 757 pediatric H1N1 inpatients from nine tertiary public hospitals in Yunnan and Shanghai, China, were retrospectively included, of which 431 patients diagnosed between February 2023 and July 2023 were divided into post-COVID-19 group, while the remaining 326 patients diagnosed between November 2018 and April 2019 were divided into pre-COVID-19 group. A 1:1 propensity-score matching (PSM) was adopted to balance demographic differences between pre- and post-COVID-19 groups, and then compared the severity across these two groups based on clinical and laboratory indicators. Additionally, a subgroup analysis in the original post-COVID-19 group (without PSM) was performed to investigate the independent risk factors for severe H1N1 infection in post-COIVD-19 era. Specifically, Least Absolute Shrinkage and Selection Operator (LASSO) regression was applied to select candidate predictors, and logistic regression was used to further identify independent risk factors, thus establishing a prediction model. Receiver operating characteristic (ROC) curve and calibration curve were utilized to assess discriminative capability and accuracy of the model, while decision curve analysis (DCA) was used to determine the clinical usefulness of the model.
RESULTS: After PSM, the post-COVID-19 group showed longer fever duration, higher fever peak, more frequent cough and seizures, as well as higher levels of C-reactive protein (CRP), interleukin 6 (IL-6), IL-10, creatine kinase-MB (CK-MB) and fibrinogen, higher mechanical ventilation rate, longer length of hospital stay (LOS), as well as higher proportion of severe H1N1 infection (all P < 0.05), compared to the pre-COVID-19 group. Moreover, age, BMI, fever duration, leucocyte count, lymphocyte proportion, proportion of CD3+ T cells, tumor necrosis factor α (TNF-α), and IL-10 were confirmed to be independently associated with severe H1N1 infection in post-COVID-19 era. A prediction model integrating these above eight variables was established, and this model had good discrimination, accuracy, and clinical practicability.
CONCLUSIONS: Pediatric H1N1 infection during post-COVID-19 era showed a higher overall disease severity than the classical H1N1 infection in pre-COVID-19 period. Meanwhile, cough and seizures were more prominent in children with H1N1 infection during post-COVID-19 era. Clinicians should be aware of these changes in such patients in clinical work. Furthermore, a simple and practical prediction model was constructed and internally validated here, which showed a good performance for predicting severe H1N1 infection in post-COVID-19 era.
A cluster of pneumonia cases and COVID-19 pandemic that started in Wuhan, China, was caused by novel beta coronavirus, the 2019 novel coronavirus (2019-nCoV). This has led to many number of deaths and many were infected worldwide owing to the absence of effective therapies against coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2). Viral maturation requires the activity of the main viral protease (Mpro) and thereby, inhibition stops the advancement of the disease. The current invention delivers a potential anti-viral drug candidates docked against COVID-19 protein targets: SARS-CoV-2 main protease, drug-likeness, efficacy, molecular docking, physicochemical and pharmacokinetic studies of novel synthesized sulfonamide analogues. Physicochemical and pharmacokinetic properties have been evaluated on the basis of certain parameters like Lipinski rule of 5 (RO5 rule) and ADMET (absorption, distribution, metabolism, excretion and toxicity). All the synthesized compounds follow Lipinski rule of five (RO5 rule) and the compounds followed the range of rotational bonds, hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), topological surface area (TPSA), number of violations, etc. All these compounds shown good pharmacokinetic properties, zero renal OCT2 substrate toxicity and negligible toxicity values. BOILED-egg model was carried out for evaluating the gastrointestinal absorption and brain penetration effect. Compounds 3b and 3d comes under white region of egg and exhibited good gastrointestinal absorption, whereas, 3a, 3c, 3e and 3f compounds fall under yellow region (yolk) of egg which showed good brain penetration effect. All novel sulfonamide analogues including commercially available anti-COVID-19 drugs, Hydroxychloquine and Umifenovir docked with COVID-19 protein targets, i.e., PDB: 6VWW & 6Y2E.Compound 3c when docked with PDB: 6VWW shown maximum energy of -22.06 kcal/mol with two hydrogen binding interactions which are better than marketed drugs. Similarly, compound 3a exhibited highest energy of -14.00 kcal/mol.
All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
Patients who continue to experience clinically significant symptoms of dry eye disease even after utilizing traditional methods of treatment for dry eye including but not limited to artificial tears, warm compresses, topical anti-inflammatories like cyclosporine and/or lifitegrast. Patients will receive repository corticotropin intramuscular injections 80 u/ml 2-3 times weekly for up to 3 months as judged by the investigator.
The invention relates to selenium-enriched wall-broken ganoderma lucidum spore particles and a preparation method thereof. Belongs to a deep processing product of ganoderma lucidum resources. The invention aims to solve the problems of great loss of active ingredients and the like in the prior ganoderma lucidum rough processing stage. The invention comprises the steps of superfine grinding of ganoderma lucidum spore powder and ganoderma lucidum, uniform mixing with selenized carrageenan, adding corn starch auxiliary materials, granulating by adopting a one-step granulating method, granulating, sub-packaging and packaging. Obtaining selenium-enriched wall-broken ganoderma lucidum spore particles. The preparation method of the selenium-enriched wall-broken ganoderma lucidum spore particles is scientific and reasonable, the effective active ingredients of the selenium-enriched wall-broken ganoderma lucidum spore particles are reserved to the maximum extent, and the quality of the selenium-enriched wall-broken ganoderma lucidum spore particles is stable. The functions of the composition are enhancing immunity, resisting cancer, resisting oxidation, antagonizing harmful heavy metals, regulating absorption and utilization of vitamin A, vitamin C, vitamin E and vitamin K, regulating synthesis of protein, enhancing reproductive function, etc.
PURPOSE:To provide a high-safety medicine for controlling body weight, containing Oolong tea saponin and Oolong tea fiber, having an excellent effect on control of body weight without a side effect and useful for, e.g. prevention and improvement of obesity or healthy diet. CONSTITUTION:Hot water of 60 to 80 deg.C is added to dried Oolong tea leaves and allowed to stand for 30 to 60min while keeping this temperature. After filtration, the resultant filtrate is heated and concentrated under vacuum and the concentrated solution is freeze dried to obtain Oolong tea saponin. Leaf vein parts are removed from dried Oolong tea leaves and the resultant material is ground using a stone mill. The ground material is then allowed to pass through a 150 to 200mesh sieve and further ground using a stone mill to obtain Oolong tea fiber. Both the obtained Oolong tea saponin and Oolong tea fiber are blended and polydextrose, lactose, cellulose, sucrose fatty acid ester, etc., are added thereto. After sufficient mixing, the resultant mixture is subjected to preparation, thus affording the objective medicine for controlling body weight, having an excellent effect on control of body weight without any side effect and useful for, e.g. prevention and improvement of obesity or healthy diet.
Women in the experimental group will be offered a series of three to five art therapy sessions, depending on the participants' needs/preferences. The art therapy sessions will be given anytime after consent has been obtained till approximately 36 weeks of gestation. The art therapy sessions are in addition to routine antenatal care.
Methods and compositions useful for the treatment and prophylaxis of calcium renal stones in persons with hypocitraturia or undergoing allopurinol therapy are disclosed. The methods involve administering potassium citrate compositions to persons afflicted with or susceptible to calcium renal stone formations. A typical dosage scheme involves administering about 30 to 120 meq potassium citrate per day in divided doses. Such treatments are effective in dissolving existing calcium stones and preventing formation of new calcium stones. Moreover, the results of a comparative clinical assay indicate the potassium citrate is superior to sodium citrate in the treatment of uric acid lithiasis. Potassium citrate therapy averts calcium renal stone formation, a complication which is often associated with sodium citrate or sodium bicarbonate alkalinization therapy.
Cardiac fibrosis is a pathological scarring process that impairs cardiac function. N-acetyltransferase 10 (Nat10) is recently identified as the key enzyme for the N4-acetylcytidine (ac4C) modification of mRNAs. In this study, we investigated the role of Nat10 in cardiac fibrosis following myocardial infarction (MI) and the related mechanisms. MI was induced in mice by ligation of the left anterior descending coronary artery; cardiac function was assessed with echocardiography. We showed that both the mRNA and protein expression levels of Nat10 were significantly increased in the infarct zone and border zone 4 weeks post-MI, and the expression of Nat10 in cardiac fibroblasts was significantly higher compared with that in cardiomyocytes after MI. Fibroblast-specific overexpression of Nat10 promoted collagen deposition and induced cardiac systolic dysfunction post-MI in mice. Conversely, fibroblast-specific knockout of Nat10 markedly relieved cardiac function impairment and extracellular matrix remodeling following MI. We then conducted ac4C-RNA binding protein immunoprecipitation-sequencing (RIP-seq) in cardiac fibroblasts transfected with Nat10 siRNA, and revealed that angiomotin-like 1 (Amotl1), an upstream regulator of the Hippo signaling pathway, was the target gene of Nat10. We demonstrated that Nat10-mediated ac4C modification of Amotl1 increased its mRNA stability and translation in neonatal cardiac fibroblasts, thereby increasing the interaction of Amotl1 with yes-associated protein 1 (Yap) and facilitating Yap translocation into the nucleus. Intriguingly, silencing of Amotl1 or Yap, as well as treatment with verteporfin, a selective and potent Yap inhibitor, attenuated the Nat10 overexpression-induced proliferation of cardiac fibroblasts and prevented their differentiation into myofibroblasts in vitro. In conclusion, this study highlights Nat10 as a crucial regulator of myocardial fibrosis following MI injury through ac4C modification of upstream activators within the Hippo/Yap signaling pathway.
The invention relates to a preparation method and application of three-dimensional polydopamine, and belongs to the technical field of functional materials. The preparation method takes dopamine and metal salt as raw materials and is prepared by utilizing a self-polymerization and self-assembly method. The size of the polydopamine material prepared by the method can be regulated. The preparation method has the advantages of simplicity, good biocompatibility, high photo-thermal conversion efficiency and the like, and realizes the requirement of environmental protection by using a simple water/alcohol system as a reaction solvent. The invention relates to a method for preparing a three-dimensional polydopamine material. Can promote the further development of the research related to the polydopamine and promote the research of the photo-thermal agent. The three-dimensional polydopamine prepared by the method has an excellent photothermal conversion effect, is a good photothermal reagent, and shows excellent biocompatibility and photothermal conversion rate compared with the traditional optical material. The three-dimensional poly-dopamine material prepared by the invention can be used for photothermal treatment of tumors, so that the material has a good medical application prospect.
The tissue-specific heart decellularized extracellular matrix (hdECM) demonstrates a variety of therapeutic advantages, including fibrosis reduction and angiogenesis. Consequently, recent research for myocardial infarction (MI) therapy has utilized hdECM with various delivery techniques, such as injection or patch implantation. In this study, a novel approach for hdECM delivery using a wet adhesive paintable hydrogel is proposed. The hdECM-containing paintable hydrogel (pdHA_t) is simply applied, with no theoretical limit to the size or shape, making it highly beneficial for scale-up. Additionally, pdHA_t exhibits robust adhesion to the epicardium, with a minimal swelling ratio and sufficient adhesion strength for MI treatment when applied to the rat MI model. Moreover, the adhesiveness of pdHA_t can be easily washed off to prevent undesired adhesion with nearby organs, such as the rib cages and lungs, which can result in stenosis. During the 28 days of in vivo analysis, the pdHA_t not only facilitates functional regeneration by reducing ventricular wall thinning but also promotes neo-vascularization in the MI region. In conclusion, the pdHA_t presents a promising strategy for MI treatment and cardiac tissue regeneration, offering the potential for improved patient outcomes and enhanced cardiac function post-MI.
Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2) and docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cancer is a major disease that endangers human health. Cancer drug resistance and relapse are the two main causes contributing to cancer treatment failure. Cancer stem cells (CSCs) are a small fraction of tumor cells that are responsible for tumorigenesis, metastasis, relapse, and resistance to conventional anticancer therapies. Therefore, CSCs are considered to be the root of cancer recurrence, metastasis, and drug resistance. Novel anticancer strategies need to face this new challenge and explore their efficacy against CSCs. Recently, immunotherapy has made rapid advances in cancer treatment, and its potential against CSCs is also an interesting area of research. Meanwhile, immunotherapy strategies are novel therapeutic modalities with promising results in targeting CSCs. In this review, we summarize the targeting of CSCs by various immunotherapy strategies such as monoclonal antibodies(mAb), tumor vaccines, immune checkpoint inhibitors, and chimeric antigen receptor-T cells(CAR-T) in pre-clinical and clinical studies. This review provides new insights into the application of these immunotherapeutic approaches to potential anti-tumor therapies in the future.
PRO140 350mg weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
HIV infected patients with stable plasma HIV-RNA below 50 copies per mL and severe liver dysfunction will be switched from their antiretroviral regimen to a combination of raltegravir (one 400 mg pill twice daily) and two fully active molecules among nucleosi(ti)de analogs and enfuvirtide for a first period of at least 3 months and a second period of at least 3 months after liver transplantation, if need be, when a steady state of the anticalcineurin will be reached. Pharmacokinetic parameters of raltegravir will be calculated during severe liver dysfunction period and after liver transplantation. Pharmacokinetic parameters of cyclosporine (or tacrolimus if contra indication to cyclosporine) will be compared when administrated alone or combined with raltegravir. Patients will be followed up according to standard of care. This study will be divided in two distinct periods (1 and 2) lasting 3 months each. Period 1 will start from the inclusion in the study and will generally include the switch to raltegravir. Period 2 will start from liver transplantation.
Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection in acute phase. Each included patient will receive a single dose of 100 million autologous bone marrow-derived mononuclear cells.
For patients in the rTMS group, we will first determine the intensity of the rTMS protocol by assessing the individual resting motor threshold (rMT). After determination of each individual's rMT, we will set rTMS intensity at 100% of the rMT and apply a single train of low-frequency rTMS over the DLPFS at 1 Hz for a total duration of 30 min (2000 pulses). receive 4 week rTMS treatment.
To output information regarding doctors, medical institutions or clinical departments capable of curing diseases in order to realize medical treatment measures in which medical service providers provide services together in cooperation.SOLUTION: A server acquires the disease name of a patient as a search condition (drop-down list 104 in FIG. 7). The server also refers to consultation history data stored in a DB server, and stores information regarding the type of medical care of a record including the disease name of the patient in a correspondence table. Meanwhile, the server refers to the correspondence table and outputs identification information regarding a doctor whose medical care type information satisfies a standard (presentation candidate in FIG. 7). Thus, it is possible to output information regarding doctors capable of curing the disease of the patient, so that the doctors confirm outputted information so as to present a suitable doctor to the patient.SELECTED DRAWING: Figure 7
PURPOSE:To provide the titled inhibitor effective especially as a hypotensor, and obtained from casein derived from cattle. CONSTITUTION:Casein derived from cattle is decomposed at 5.5-9.0pH with trypsin, and the decomposition product is treated with heat at about 100 deg.C or with an acid to precipitate trypsin and undecomposed casein. The precipitate is removed, e.g. by centrifugal separation. The obtained mother liquid is neutralized with an alkali such as NaOH and concentrated 1/2-1/3 times under reduced pressure. The concentrate is purified, dissolved in a 0.04M phosphate buffer solution at 6.0-8.0pH, and treated with peptidase. The enzyme is thermally inactivated and removed from the system. The mother liquid is separated and purified by high-speed liquid chromatography, and the obtained peptide fraction is concentrated in vacuum, desalted, and concentrated in vacuum to obtain the angiotensinase inhibitor of formula as white powder. The inhibitor can be applied to mammals which produce said enzyme in the body.